These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6287202)

  • 1. Inhibition of aggregation and stimulation of cyclic AMP generation in intact human platelets by the diterpene forskolin.
    Siegl AM; Daly JW; Smith JB
    Mol Pharmacol; 1982 May; 21(3):680-7. PubMed ID: 6287202
    [No Abstract]   [Full Text] [Related]  

  • 2. Receptor (norepinephrine), P-site (2',5'-dideoxyadenosine), and calcium-mediated inhibition of prostaglandin and forskolin-activated cyclic AMP-generating systems in human platelets.
    Siegl AM; Daly JW
    J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(3):229-45. PubMed ID: 2991349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of cyclic AMP metabolism in human platelets. Sequential activation of adenylate cyclase and cyclic AMP phosphodiesterase by prostaglandins.
    Alvarez R; Taylor A; Fazzari JJ; Jacobs JR
    Mol Pharmacol; 1981 Sep; 20(2):302-9. PubMed ID: 6272089
    [No Abstract]   [Full Text] [Related]  

  • 4. The increased sensitivity of platelets to prostacyclin in marathon runners.
    Dix CJ; Hassall DG; Bruckdorfer KR
    Thromb Haemost; 1984 Jul; 51(3):385-7. PubMed ID: 6093280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of diterpene forskolin on the release reaction and protein phosphorylation of human platelets.
    González A; Aranda E; Mezzano D; Garrido J
    Cell Biochem Funct; 1983 Oct; 1(3):179-85. PubMed ID: 6088107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of low-density lipoproteins on the synthesis of cyclic nucleotides induced by prostacyclin in isolated platelets.
    Bruckdorfer KR; Buckley S; Hassall DG
    Biochem J; 1984 Oct; 223(1):189-96. PubMed ID: 6093767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of forskolin on platelet deaggregation and cyclic AMP generation.
    Kariya T; Morito F; Sakai T; Takahata K; Yamanaka M
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Oct; 331(1):119-21. PubMed ID: 2999615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostacyclin analogs: antiaggregatory potency and enhancement of cAMP levels in human platelet rich plasma.
    Dembinska-Kiec A; Rücker W; Schönhöfer PS; Gandolfi C
    Thromb Haemost; 1979 Dec; 42(4):1340-3. PubMed ID: 232318
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition by forskolin of cytosolic calcium rise, shape change and aggregation in quin2-loaded human platelets.
    Sage SO; Rink TJ
    FEBS Lett; 1985 Aug; 188(1):135-40. PubMed ID: 2410292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous antiaggregatory prostaglandins can contribute to inhibition of hemostasis: a pharmacological study in vivo in humans.
    Gresele P; Arnout J; Deckmyn H; Vermylen J
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():248-53. PubMed ID: 2821758
    [No Abstract]   [Full Text] [Related]  

  • 11. Modified sensitivity of diabetic platelets to prostacyclin.
    Bonne C; Romquin N; Regnault F
    Bibl Anat; 1979; (18):98-103. PubMed ID: 227357
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyclic nucleotides in hypertension.
    Hamet P; Franks DJ; Adnot S; Coquil JF
    Adv Cyclic Nucleotide Res; 1980; 12():11-23. PubMed ID: 6250345
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of thromboxane antagonist EP 045 on platelet aggregation.
    Jones RL; Wilson NH; Armstrong RA; Peesapati V; Smith GM
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():345-50. PubMed ID: 6303074
    [No Abstract]   [Full Text] [Related]  

  • 14. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
    Bilodeau ML; Hamm HE
    J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms of action of prostaglandins on the thrombocyte-vascular wall system].
    Gabrielian ES; Akopov SE; Badzhinian SA
    Vestn Akad Med Nauk SSSR; 1984; (11):63-8. PubMed ID: 6099016
    [No Abstract]   [Full Text] [Related]  

  • 16. [Mechanism of platelet aggregation inhibition].
    Abiko Y; Ashida S
    Rinsho Byori; 1979; Suppl 40():169-80. PubMed ID: 233105
    [No Abstract]   [Full Text] [Related]  

  • 17. The cytoplasmic concentration of free calcium in platelets is controlled by stimulators of cyclic AMP production (PGD2, PGE1, forskolin).
    Feinstein MB; Egan JJ; Sha'afi RI; White J
    Biochem Biophys Res Commun; 1983 Jun; 113(2):598-604. PubMed ID: 6307295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanism of action of different inhibitors of thrombocyte aggregation].
    Lakin KM; Makarov VA; Novikova NV; Muliar AG
    Vestn Akad Med Nauk SSSR; 1984; (11):54-63. PubMed ID: 6099015
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of PGI2 and di-butyryl cyclic-AMP on platelets exposed to shear stress.
    Hardwick RA; Hellums JD; Peterson DM; Moake J; Olson J
    Trans Am Soc Artif Intern Organs; 1981; 27():192-6. PubMed ID: 6277071
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanism involved in the antiplatelet activity of naloxone in human platelets.
    Sheu JR; Hung WC; Lee LW; Chang PT; Kan YC; Yen MH
    Biochem Biophys Res Commun; 1997 Feb; 231(1):12-6. PubMed ID: 9070210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.